Biospecimen Core

生物样本核心

• 批准号: 10290163
• 负责人: Charles V Clevenger
• 金额: $ 18.31万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-20 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10290163
• 关键词: Address; Agreement; Artificial Intelligence; Bioinformatics; Biological Specimen Banks; Biometry; Blood specimen; Cancer Center; Cancer Patient; Center for Translational Science Activities; City of Hope Comprehensive Cancer Center; Clinical; Clinical Data; Collaborations; Collection; Confidentiality of Patient Information; Consent; Data; Data Element; Databases; Dedications; Development; Disease; Documentation; Early Detection Research Network; Ensure; European; Excision; Faculty; Formalin; Freezing; Future; Goals; Health; Hospital Information Systems; Housing; Human; Individual; Informatics; Institution; Institutional Review Boards; Investigation; Lead; Link; Liquid substance; Malignant Neoplasms; Malignant neoplasm of lung; Massey Cancer Center at the Virginia Commonwealth University; Medical; Molecular; Molecular Analysis; National Cancer Institute; Outcome; Paraffin Embedding; Pathologic; Pathology; Pathology Report; Procedures; Process; Reproducibility; Research; Research Personnel; Research Project Grants; Secure; Site; Source; South Carolina; Specimen; Standardization; Techniques; Technology; Time; Tissue Banks; Tissue Embedding; Tissues; Translational Research; United States National Aeronautics and Space Administration; Universities; Virginia; base; behavioral health; biobank; cancer health disparity; cancer risk; data repository; diversity and inclusion; ethnic minority population; health data; high risk; human tissue; programs; racial diversity; racial minority; sample collection; social determinants; social health determinants; survival outcome; translational study

BIOSPECIMEN-PATHOLOGY CORE: PROJECT SUMMARY Most biospecimens in the US are collected from individuals of Northern European ancestry, limiting the generalizability of findings. There is an urgent need to increase the availability of high-quality biospecimens from ethnic and racial minorities for translational lung cancer disparities research. A significant goal of the Translational Research Center in Lung Cancer Disparities (TRACER) Biospecimen/Pathology Core (BPC) is to coordinate efforts related to collection, processing, storage, and distribution of annotated human biospecimens for all participating sites and projects, including the a future pilot research projects supported by the Developmental Research Program (DRP). The TRACER BPC team brings together experts with a shared dedication to eradicating disparities, and this union will be formalized by institutional agreements and standard operating procedures (SOPs). The TRACER BPC will provide translational disparities researchers access to an expanded array of biospecimens, analytical techniques, and annotations with clinical data as well as social determinants of health data. The BPC Lead and Co-Leads are established leaders in lung cancer pathology, biorepositories, cancer informatics, geospatial analysis, behavioral health and cancer biologists offering molecular analysis techniques – all committed to disparities and translational research. TRACER BPC specimens will be jointly housed at the Massey Cancer Center at Virginia Commonwealth University VCU), the Hollings Cancer Center at the Medical University South Carolina (MUSC) and the City of Hope Comprehensive Cancer Center. VCU will be the central IRB, andcommon SOPs, data elements, and platforms will be established. VCU will compile and integrate data, and data will be uploaded to the Jet Propulsion Lab (JPL; NASA) server. JPL houses and integrates the Early Detection Research Network (EDRN) data. Housing TRACER data with JPL will facilitate future TRACER-EDRN collaborations. Aim 1 will provide a portal through which TRACER collaborative investigators can acquire through uniform SOP’s the human tissues, fluids, and blood samples for research projects of this P20 with high rigor and reproducibility. Aim 2 will collect and annotate specimens including demographic data, clinical data, histopathologic results, molecular annotation and social determinants of health data. Working with the TRACER Biostatistics and Bioinformatics Core, TRACER investigators will have access to a fully integrated centralized information source. Aim 3 will expand TRACER investigators’ access to cutting-edge technology and artificial intelligence analytics through a partnership with the National Cancer Institute’s Early Detection Research Network (EDRN).

生物标本-病理学核心：项目总结 美国的大多数生物标本是从北方欧洲血统的个体中收集的， 调查结果的普遍性。迫切需要增加高质量生物标本的供应， 少数民族和种族的肺癌差异研究。一个重要的目标， 肺癌差异转化研究中心（TRACER）生物标本/病理学核心（BPC）将 协调与带注释的人类生物标本的采集、处理、储存和分发相关的工作 所有参与的地点和项目，包括由 发展研究计划（DRP）。TRACER BPC团队将专家聚集在一起， 致力于消除差距，这一联盟将通过机构协议和标准正式化。 操作程序（SOP）。TRACER BPC将为翻译差异研究人员提供访问 扩展的生物标本、分析技术和临床数据注释以及社会 健康数据的决定因素。BPC领导者和共同领导者是肺癌病理学领域公认的领导者， 生物储存库、癌症信息学、地理空间分析、行为健康和癌症生物学家， 分子分析技术-所有致力于差异和转化研究。TRACER BPC 标本将共同存放在弗吉尼亚联邦大学梅西癌症中心（VCU）， 南卡罗来纳州医科大学霍林斯癌症中心（MUSC）和希望之城综合医院 癌症中心VCU将成为中心IRB，并将建立通用SOP、数据元素和平台。 VCU将编译和整合数据，并将数据上传到喷气推进实验室（JPL; NASA）服务器。 喷气推进实验室收集和整合早期探测研究网络（EDRN）的数据。住房TRACER数据， JPL将促进未来的TRACER-EDRN合作。目标1将提供一个门户， 合作调查人员可以通过统一的SOP获取人体组织、体液和血液样本， 该P20的研究项目具有高度的严谨性和可重复性。目标2将收集和注释标本 包括人口统计学数据、临床数据、组织病理学结果、分子注释和社会决定因素 健康数据。与TRACER生物统计学和生物信息学核心合作，TRACER研究人员将 访问完全集成的集中式信息源。目标3将扩大TRACER研究人员的访问权限， 尖端技术和人工智能分析，通过与国家癌症研究所的合作， 早期检测研究网络（EDRN）。